Original Paper. Time Since Last Use of Oral Contraceptives and Risk of Invasive Cervical Cancer
|
|
- Roy Simpson
- 6 years ago
- Views:
Transcription
1 Pergamon European Journal of Cancer, Vol. 34, No. 6, pp. 884±888, 1998 # 1998 Elsevier Science Ltd. All rights reserved Printed in Great Britain /98 $ PII: S (97) Original Paper Time Since Last Use of Oral Contraceptives and Risk of Invasive Cervical Cancer F. Parazzini, 1,2 L. Chatenoud, 1 C. La Vecchia, 1,3 F. ChiaVarino, 1 E. Ricci 1 and E. Negri 1 1 Istituto di Ricerche Farmacologiche `Mario Negri', via Eritrea 62, Milan; 2 Prima Clinica Ostetrico Ginecologica, Divisione di Oncologia Ginecologica, Istituto Nazionale Tumori, UniversitaÁ di Milano, via Commenda 12, Milan; and 3 Istituto di Statistica Medica e Biometria, UniversitaÁ di Milano, via Venezian 1, Milan, Italy The time±risk relationship for the association between cervical cancer and oral contraceptives (OC) was examined using data on 592 cases of invasive cervical cancer aged 60 years or less and 616 controls with acute, non-gynaecological, non-hormone-related, non-neoplastic diseases. A total of 125 cases and 114 controls reported ever using OC and the multivariate odds ratio (OR) for ever versus never users was 1.21 (95% con dence interval (CI) 0.82±1.74). The risk of invasive cervical cancer was above unity in current users (OR 1.23) and in women who had stopped OC use less than 10 years before diagnosis, but not in those who had stopped their OC use 10 years before (OR 0.85). Similarly, the OR was less for women who had started OC use 15 years or more previously than for more recent users. These data suggest that OCs may have a late stage (promoter) evect on cervical carcinogenesis and thus have public health implications, since the incidence of invasive cervical cancers is low at young ages, when OC use is more common and increases during middle age. The absence of a persisting risk is therefore of interest both for assessing individual risk and for its public health implications. # 1998 Elsevier Science Ltd. All rights reserved. Key words: cervical cancer, oral contraceptives, risk factors Eur J Cancer, Vol. 34, No. 6, pp. 884±888, 1998 INTRODUCTION Several epidemiological studies have suggested that parous women and oral contraceptive (OC) users are at increased risk of invasive cervical cancer [1±4]. In biological terms, it has been postulated that oestrogen±progestin stimulation can favour, or promote, cervical carcinogenesis, possibly through glucocorticoid-dependent oncogenic transformation by selected papilloma virus types [5]. This suggests that hormonal stimulation may act on one of the latter stages of the process of cervical carcinogenesis. A detailed analysis of the risk relationship over time of any association between cervical cancer and OCs may, therefore, help elucidate the role of hormonal correlates of cervical carcinogenesis, as well as de ne the bene t/risk pro le of OCs. For example, an update of the Oxford Family Planning Correspondence to F. Parazzini. Received 25 Jul. 1997; revised 5 Nov. 1997; accepted 3 Dec Association cohort study indicated that the elevated risk of cervical cancer associated with OC use was essentially con- ned to current or recent long-term users [6]. To provide further information on these issues, we considered data collected in a large case±control study of cervical neoplasia conducted in Italy. MATERIALS AND METHODS This was a hospital-based case±control investigation conducted in the greater Milan area, northern Italy between 1981 and Its general design has been described in previous papers including a subset of subjects considered in this report [4, 7]. Cases were 592 histologically con rmed invasive cervical cancers below the age of 61 years (range 17±60 years, median 48 years) admitted to a network of Obstetrics and Gynaecology Departments in the great Milan area. The comparison group consisted of 616 women aged 60 years or less (range 16±60 years, median 48 years), 884
2 Oral Contraceptives and Cervical Cancer 885 Table 1. Distribution of 592 invasive cervical cancer cases and 616 controls according to age and selected factors, Milan, Italy 1981±1993 Number of cases (%) Number of controls (%) Multivariate odds ratio (95% CI)* Age (years) < (25.5) 170 (27.6) ± 40± (30.7) 161 (26.1) ± 50± (43.7) 285 (46.2) ± Education (years) < (63.0) 310 (50.3) 1y 7± (21.5) 185 (30.0) 0.71 (0.53±0.98) (15.5) 121 (19.6) 0.78 (0.54±1.16) Smoking habits Never smokers 380 (64.2) 398 (64.6) 1y Ever smokers 212 (35.8) 218 (35.4) 1.06 (0.80±1.42) Parity 0 54 (9.1) 130 (21.1) 1y 1±2 310 (52.4) 346 (56.2) 3.11 (2.08±4.69) (38.5) 140 (22.7) 5.42 (3.48±8.56) Lifelong number of sexual partners 0 4 (0.7) 35 (5.7) 0.22 (0.07±0.67) (69.8) 457 (74.2) 1y 2 81 (13.7) 62 (10.1) 1.80 (1.20±2.70) 3 86 (14.5) 49 (7.9) 3.85 (1.91±4.32) Unreported 8 (1.4) 13 (2.1) ± Lifelong number of normal Pap smears (57.1) 161 (26.1) 1y 1 90 (15.2) 89 (14.4) 0.39 (0.27±0.57) 2 91 (15.4) 63 (10.2) 0.26 (0.16±0.41) 3 70 (11.8) 296 (48.1) 0.15 (0.11±0.21) Unreported 3 (0.5) 7 (1.1) Abnormal Pap smearsz Never 240 (94.5) 441 (96.9) 1y Ever 14 (5.5) 14 (3.1) 1.49 (0.61±3.20) CI, con dence interval. *Multivariate estimates including terms for age, education, calendar year at interview, smoking habits, parity, lifelong number of sexual partners and of Pap smears, and oral contraceptive use. yreference categories. zone year before interview or more. Table 2. Distribution of 592 invasive cervical cancer cases and 616 controls according to selected measures of oral contraceptive (OC) use, corresponding odds ratios (OR) and 95% con dence intervals (CI), Milan, Italy 1981±1993 OR (95% CI)* Number of cases (%) Number of controls (%) Age-adjusted Multivariate OC use Ever use 125 (21.1) 114 (18.5) 1.21 (0.89±1.64) 1.21 (0.82±1.74) Duration of OC use (months) (10.5) 56 (9.1) 1.23 (0.82±1.83) 1.17 (0.75±1.82) > (10.6) 56 (9.1) 1.32 (0.81±2.15) 1.31 (0.72±2.39) Unknown ± 2 (0.4) ± ± w 2 1 trend 1.33 (P = 0.25) 3.05 (P = 0.08) Time since last use (years) Current 19 (3.2) 23 (3.7) 1.01 (0.53±1.94) 1.33 (0.65±2.70) 1± < 3 23 (3.9) 17 (2.8) 1.61 (0.82±3.13) 1.56 (0.74±3.29) 3± < 6 22 (3.7) 16 (2.6) 1.60 (0.81±3.17) 1.47 (0.69±3.14) 6± < (4.4) 17 (2.8) 1.63 (0.86±3.09) 1.66 (0.83±3.34) (5.9) 41 (6.7) 0.90 (0.56±6.45) 0.85 (0.51±1.43) Time since rst use (years) 5 26 (4.4) 25 (4.1) 1.33 (0.72±2.45) 1.49 (0.76±2.94) 6± < (6.1) 22 (3.6) 1.89 (1.06±3.35) 1.77 (0.93±3.37) 11± < (5.1) 32 (5.2) 1.02 (0.60±1.74) 1.07 (0.60±1.90) (5.6) 35 (5.7) 0.98 (0.60±1.61) 0.96 (0.55±1.65) Age at rst OC use < (6.4) 40 (6.5) 1.12 (0.68±1.86) 1.12 (0.63±1.97) 25±29 35 (5.9) 35 (5.7) 1.10 (0.66±1.83) 1.10 (0.63±1.92) (8.8) 39 (6.3) 1.35 (0.87±2.10) 1.36 (0.83±2.23) *Multivariate estimates including terms for age, education, calendar year at interview, parity, number of sexual partners, smoking habits and number of Pap smears. yreference category.
3 886 F. Parazzini et al. with acute, non-gynaecological, non-hormone-related, nonneoplastic diseases and who had not undergone total hysterectomy, admitted to the same network of hospitals where the cases had been identi ed, and from comparable catchment areas. Of these, 26% were admitted for traumatic conditions (mostly fractures and sprains), 35% had nontraumatic orthopaedic disorders (mostly lower back pain and disc disorders), 14% surgical conditions (mostly abdominal, such as acute appendicitis or strangulated hernia) and 24% had other illnesses, such as ear, nose and throat or dental disorders. Less than 2% of eligible women (cases and controls) refused to be interviewed. A structured questionnaire was used to collect information on personal characteristics and habits, education and other socio-economic factors, general lifestyle habits, such as smoking, alcohol and covee consumption, frequency of consumption of a few indicator foods, selected indicators of sexual habits, menstrual and reproductive history, related medical history, and history of lifelong use of OCs and female hormone preparations for any other indication, including time and duration of each episode of use and the brand name, whenever available. In addition, information on the lifetime number of Pap smears was collected. Odds ratios (OR) of cervical cancer, and the corresponding 95% con dence intervals (CI) for various measures of OC use were derived using unconditional multiple logistic regression, tted by the method of maximum likelihood [8], including terms for age in quinquennia, education ( < 7, 7±11, 12 years), calendar year and interview, smoking habits (ever, never), parity (0, 1±2, 3), number of partners (0, 1, 2) and of Pap smears (0, 1, 2, 3). RESULTS Table 1 shows the distribution of cases and controls according to age and selected covariates. Cases were less educated, more frequently multiparous, reported a lifelong larger number of sexual partners and less frequently underwent Pap smears. In Table 2, diverent measures of OC use are considered. A total of 125 cases and 114 controls reported ever using OCs. The corresponding OR was 1.21 (95% CI 0.82±1.74, multivariate). The ORs were 1.17 in users for 24 months or less and 1.31 in users for > 24 months (multivariate; w 2 1 trend 3.05, P = 0.08). The risk of invasive cervical cancer was above unity for current users or in women who had stopped use less than 10 years before they were interviewed, but not in those who stopped their OC use 10 years before, whose OR was 0.85 (95% CI 0.51±1.43, multivariate). Likewise, in comparison with never users, the OR was 0.96 (95% CI 0.55±1.65, multivariate) for women who had started OC use 15 or more years previously. There was no clear relationship between age at rst OC use and risk of cervical cancer. Table 3 shows the analyses of the relationship between the time since last OC use and the risk of invasive cervical cancer in strata of selected covariates. The ORs were systematically higher in current OC users or ex-users from less than 10 years before, than in those who had stopped OC use for 10 years or more. The association with recent use was apparently stronger in less educated, multiparous women, who had never undergone a Pap smear (i.e. at baseline high risk). For example, the OR of cervical cancer in women reporting the time since last OC use as < 10 years was 2.22 in women Table 3. Multivariate odds ratios (ORs)* of invasive epithelial cervical cancer [and corresponding con dence intervals (CI)] according to time since last oral contraceptive (OC) use in strata of selected covariates, Milan, Italy 1981±1993 Time since last OC use Never OC use Current < 10 years 10 years Total 1y 1.23 [0.60±2.44]z 1.57 [0.99±2.49] 0.85 [0.51±1.43] (19:23) (71:50) (35:41) Age (years) < 45 1y 1.26 [0.59±2.71] 1.42 [0.83±2.41] 0.67 [0.29±1.55] (17:21) (60:42) (14:18) 45±60 1y 0.64 [0.08±5.07] 1.53 [0.55±4.23] 0.99 [0.51±1.93] (2:2) (11:8) (21:23) Number of sexual partners 0±1 1y 1.38 [0.49±3.87] 1.41 [0.80±2.50] 1.10 [0.59±2.05] (8:11) (36:33) (26:26) 2 1y 0.94 [0.35±2.47] 1.74 [0.80±3.79] 0.51 [0.19±1.60] (11:12) (35:17) (9:15) Education (years) < 7 1y 0.70 [0.16±2.99] 2.22 [1.10±4.50] 1.13 [0.54±2.35] (4:6) (39:17) (21:18) 7 1y 1.24 [0.55±2.80] 1.12 [0.60±2.09] 0.62 [0.27±1.37] (15:17) (32:33) (14:23) Parity 0±1 1y 1.25 [0.44±2.51] 1.24 [0.61±2.54] 1.10 [0.44±3.07] (13:15) (20:27) (9:12) > 2 1y 0.95 [0.30±3.07] 1.97 [1.07±3.62] 0.89 [0.48±1.66] (6:8) (51:23) (26:29) Lifetime number of Pap smears 0±1 1y 0.65 [0.22±1.86] 2.30 [1.06±4.97] 1.32 [0.56±3.07] (8:10) (45:10) (24:8) 2 1y 1.28 [0.50±3.29] 1.10 [0.60±2.01] 0.59 [0.28±1.24] (10:12) (26:40) (11:33) *Multivariate estimates including terms for age, education, calendar year at interview, parity, number of partners, smoking habits and number of Pap smears. yreference category. z95% con dence interval.
4 Oral Contraceptives and Cervical Cancer 887 Table 4. Main results from selected studies on recency and duration of oral contraceptive use and risk of invasive cervical cancer Author, year [ref.] Type of study Number of cases Years of use Relative risk* Years since last use Relative risk* Peters and associates, 1986 [11] Brinton and associates, 1986 [12] Ebeling and associates, 1987 [13] Irwin and associates, 1988 [14] Beral and associates, 1988 [15] Cuzick and associates, 1989 [16] Brinton and associates, 1990 [17] Bosch and associates, 1992 [18] Case±control 200 < ± ± 2± Case±control 479 < ±9 2.0 > ± ± Case±control 129 1±3 1.1 Previous use 1.2 4±6 1.2 Present use Case-control 149 < < ± ±4 1.0 Cohort 65 < y 5± Case±control 135 < (including 55 CIN III, 1± micro-invasive, > 3± invasive cancers) > Case±control 667 < ±9 1.3 > Case±control 436 1±9z ±9x WHO, 1993 [19] Case±control < ±1 1.2 > 1±3 1.6 > 1±2 1.1 > 3±8 1.2 > 2±3 1.2 > 8± > 3±5 1.4 > > 5±8 1.5 > Eluf-Neto and associates, 1994 [20] Zonderwan and associates, 1996 [6] (Oxford FPA) Case±control 199 1± Cohort 33 1± > 2±6 2.8 > 2±6 2.6 > > *Reference category: never users. yrate ratio. zhuman papillomavirus negative cases. xhuman papillomavirus positive cases. reporting < 7 years of education and 2.30 in those reporting 0±1 lifetime Pap smears. DISCUSSION In this study, the risk of invasive epithelial cervical cancer tended to be elevated in ever-users of OC and to increase with duration of use, but the trend in risk was not signi cant. The risk seems to be similar to that among current users, up to 10 years since last use, before decreasing for women who had last used OCs more than 10 years ago. These ndings agree with the suggestion [6] that the excess risk of cervical cancer is largely restricted to current or recent long-term OC users and tends to decline with time since last use. Consequently, the present data suggest that the evect of oestroprogestins would be on one of the late stages of the process of cervical carcinogenesis (i.e. promotion). Potential limitations of this study should be considered. OC users may tend to be more frequently screened by Pap smear [9]. This potential selection mechanism should lead to an underestimate of the role of OCs, particularly in the short term and in the present analysis the evect of OCs on cervical cancer risk was larger in women who did not report any Pap smear during their life. With regard to other covariates (chie y education and sexual habits), their inclusion in the multivariate analysis did not drastically change any of the ORs. With reference to information bias, the similar clinical setting should favour a comparable recalling of drug use (including OCs) among cases and controls [10]. The questions regarding OC use were derived from a questionnaire including more than 100 questions, analysing general characteristics, reproductive and medical history and general lifestyle habits. Further, the analysis of the relationship between OC use and cervical cancer risk was not the main objective of the study and the interviewers, as well as the women interviewed, were not aware of the potential association between OC use and the risk of invasive cervical cancer. This association, moreover, had not gained widespread attention in the lay press in Italy. Selection bias should also not be a major problem in the study, since cases and controls were identi ed in institutions covering broadly comparable catchment areas and participation was almost complete. It is unlikely that any possible source of bias had speci cally in uenced the time±risk relationship of any OC±cervical cancer risk.
5 888 F. Parazzini et al. The results of the study are in general agreement with a recent update of the Oxford Family Planning Association contraceptive study [6], in that ever users of OCs had an elevated OR of cervical invasive neoplasm. In that study, the separate evects of time since last use and duration of use were examined and the risk was largely con ned to current or recent ( < 2 years), long-term users of OCs. The potential confounding by number of sexual partners and of cervical smears could not be taken into account, but it was thought that this was unlikely to have introduced major bias. Similar ndings also emerged in other studies. Table 4 shows the results of selected published papers on the relationship between recency and duration of OC use and risk of invasive cervical cancer. In biological terms, the evect of OC use in cervical carcinogenesis may be attributed to the progestin component of the pill. HPV-16, the most important cause of cervical cancer, contains a progesterone/glucocorticoid response element upstream to the common E6-E7 promoter [21] and progesterone enhances the transferring evect of HPV-16 DNA [22]. In fact, papillomavirus lesions are exacerbated during pregnancy [23], and cervical cancer risk is enhanced by OCs and pregnancy, when progestogen levels are relatively high. Otherwise, oestrogen (prolonged by local 16a-hydroxylation) increases human papillomavirus expression via upregulation of the progesterone receptor [24]. This line of reasoning indicates that, in terms of clinical and public health implications, OC use should be critically reconsidered for women with a diagnosis of cervical intraepithelial neoplasia. However, little association between OC use and cervical cancer emerged in screened women, suggesting that, from a public health perspective, any potential impact of OC on cervical cancer risk use would be largely controlled by Pap screening. The major public health implications of this study, however, are the reassuring evidence on the absence of persisting cervical cancer risk in the medium±long term after stopping OC use. This is of particular interest, since the incidence of invasive cervical cancer is low at a younger age (i.e. below age 35 years), when OC use is most common and increases throughout middle age. Speci c attention to screening for cervical neoplasia, in contrast, would be recommended for OC users above the age of 40 or 45 years. 1. Brinton LA. Epidemiology of cervical cancerðoverview. In MunÄoz N, Bosch FX, Shah KV, Meheus. A, eds. The Epidemiology of Cervical Cancer and Human Papillomavirus. Lyon, International Agency for Research on Cancer IARC, 1992, 3± Brinton LA, Hamman RF, Huggins GR, et al. Sexual and reproductive risk factors for invasive squamous cell cervical cancer. J Natl Cancer Inst 1987, 79, 23± Hidesheim A, Reeves WC, Brinton LA, et al. Association of oral contraceptive use and human papillomaviruses in invasive cervical cancer. Int J Cancer 1990, 45, 860± Parazzini F, La Vecchia C, Negri E, Cecchetti G, Fedele L. Reproductive factors and the risk of invasive and intra-epithelial cervical neoplasia. Br J Cancer 1989, 59, 805± Pater MM, Hughes GA, Hyslop DE, Nakshatri H, Pater A. Glucocorticoid-dependent oncogenic transformation by type 16 but not type 11 human papilloma virus DNA. Nature 1988, 335, 832± Zondervan KT, Carpenter LM, Painter R, Vessey MP. Oral contraceptives and cervical cancerðfurther ndings from the Oxford Family Planning Association contraceptive study. Br J Cancer 1996, 73, 1291± Parazzini F, La Vecchia C, Negri E, Maggi R. Oral contraceptive use and invasive cervical cancer. Int J Epidemiol 1990, 19, 259± Baker NJ, Nelder JA. The GLIM System, Release 3. Oxford, Numerical Algorithms Group, Parazzini F, Negri E, Ricci E, Franceschi S, La Vecchia C. Correlates of oral contraceptive use in Italian women, 1991±93. Contraception 1996, 54, 101± Paganini-Hill A, Ross RK. Reliability of recall of drug usage and other health-related information. Am J Epidemiol 1982, 116, 114± Peters RK, Thomas D, Hagan DG, Mack TM, Henderson BE. Risk factors for invasive cervical cancer among latinas and nonlatinas in Los Angeles county. J Natl Cancer Inst 1986, 77, 1063± Brinton LA, Huggins GR, Lehman HF, et al. Long-term use of oral contraceptives and risk of invasive cervical cancer. Int J Cancer 1986, 38, 339± Ebeling K, Nischan P, Schindler Ch. Use of oral contraceptives and risk of invasive cervical cancer in previously screened women. Int J Cancer 1987, 39, 427± Irwin KL, Rosero-Bixby L, Oberle MW, et al. Oral contraceptives and cervical cancer risk in Costa Rica. J Am Med Assoc 1988, 259, 59± Beral V, Hannaford P, Kay C. Oral contraceptive use and malignancies of the genital tract. Lancet 1988, 127, Cuzick J, De Stavola B, McCance D, et al. A case±control study of cervix cancer in Singapore. Br J Cancer 1989, 60, 238± Brinton LA, Reeves WC, Brenes MM, et al. Oral contraceptive use and risk of invasive cervical cancer. Int J Epidemiol 1990, 19, 4± Bosch FX, Munoz N, De Sanjose S, et al. Risk factors for cervical cancer in Colombia and Spain. Int J Cancer 1992, 52, 750± WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Invasive squamous-cell cervical carcinoma and combined oral contraceptives: results from a multinational study. Int J Cancer 1993, 55, 228± Eluf-Neto J, Booth M, Munoz N, Bosch FX, Meijer CJLM, Walboomers JMM. Human papillomavirus and invasive cervical cancer in Brazil. Br T Cancer 1994, 69, 114± Chan WK, Klock G, Bernard HV. Progesterone and glucocorticoid response elements occur in the long control regions of several human papillomaviruses involved in anogenital neoplasia. J Virol 1989, 63, 3261± Pater A, Bayatiour M, Pater MM. Oncogenic transformation by human papillomavirus type 16 deoxyribonucleic acid in the presence of progesterone or progestins from oral contraceptives. Am J Obstet Gynec 1990, 162, 1099± Schneider A, Hotz M, Gissmann I. Increased prevalence of human papillomaviruses in the lower genital tract of pregnant women. Int J Cancer 1987, 40, 198± Monsonego J, Magdelenat H, Catalan F, Coscas Y, Zerat L, Sastre X. Estrogen and progesterone receptors in cervical human papillomavirus related lesions. Int J Cancer 1991, 48, 533±539. AcknowledgementsÐThis work was conducted within the framework of the CNR (Italian National Research Council) Applied Projects `Clinical Applications of Oncological Research' (Contract no PF39) and `Risk Factors for Disease' (Contract no PF41), and with the contribution of the Italian Association for Cancer Research and the Italian League against Tumours. The authors with to thank Ms Ivana Garimoldi for editorial assistance.
Determinants of sexual habits in Italian females
394 Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy F Parazzini L Cavalieri d'oro E Negri C La Vecchia Ii Clinica Ostetrico Ginecologica, Universita di Milano, Milan, Italy F Parazzini
More informationFREQUENCY AND RISK FACTORS OF CERVICAL Human papilloma virus INFECTION
Arch. Biol. Sci., Belgrade, 66 (4), 1653-1658, 2014 DOI:10.2298/ABS1404653M FREQUENCY AND RISK FACTORS OF CERVICAL Human papilloma virus INFECTION IN WOMEN IN MONTENEGRO GORDANA MIJOVIĆ 1, TATJANA JOVANOVIĆ
More information2. Studies of Cancer in Humans
346 IARC MONOGRAPHS VOLUME 72 2. Studies of Cancer in Humans 2.1 Breast cancer 2.1.1 Results of published studies Eight studies have been published on the relationship between the incidence of breast cancer
More informationAppendix 1. Supplementary Methods
Appendix 1. Supplementary Methods The report on one high-quality study 34 provided only estimates of associations between cervical cancer incidence and IUD use for less than 5 years (versus never) and
More informationShrestha P CORRESPONDENCE
NJOG 2015 Jul-Dec; 20 (2):45-49 Original Article Shrestha P 1 2 2 1 Department of Obstetrics and Gynecology, Patan Academy of Health Science, Lalitpur, 2 Department of Obstetrics and Gynecology, Tribhuvan
More informationPromoting Cervical Screening Information for Health Professionals. Cervical Cancer
Promoting Cervical Screening Information for Health Professionals Cervical Cancer PapScreen Victoria Cancer Council Victoria 1 Rathdowne St Carlton VIC 3053 Telephone: (03) 635 5147 Fax: (03) 9635 5360
More informationAssociation of Oral Contraceptives and Female Reproductive Tract Carcinomas
Original article: Association of Oral Contraceptives and Female Reproductive Tract Carcinomas 1 Ruchi Ramkishor Asawa, 2 Dr. Rohan Kharde 1Final year M.B.B.S. student, Rural Medical College, Loni 2Assistant
More informationDietary glycemic index, glycemic load and ovarian cancer risk: a case control study in Italy
Original article Annals of Oncology 14: 78 84, 2003 DOI: 10.1093/annonc/mdg022 Dietary glycemic index, glycemic load and ovarian cancer risk: a case control study in Italy L. S. A. Augustin 1,2, J. Polesel
More informationSIRI FORSMO,* BJARNE K JACOBSEN* AND HELGE STALSBERG t
International Journal of Epidemiology O International Epldemtologlcal Association 1996 Vol. 25, No. 1 Printed In Great Britain Cervical Neoplasia in Pap Smears: Risk of Cervical Intra-Epithelial Neoplasia
More information2. Studies of Cancer in Humans
50 2.1 Breast cancer 2.1.1 Background 2. Studies of Cancer in Humans In the previous evaluation of exogenous hormones and risk for cancer in women (IARC, 1999), the overall assessment of the use of combined
More informationThe Korean Journal of Cytopathology 15 (1) : 17-27, 2004
5 The Korean Journal of Cytopathology 5 () : 7-7, / 5 / / (human papillomavirus, HPV), 6%, 5% HPV. HPV HPV. HPV HPV,,5 HPV HPV. HPV, 6 HPV. HPV HPV International Agency for Research on Cancer (IARC) HPV
More informationOlio di oliva nella prevenzione. Carlo La Vecchia Università degli Studi di Milano Enrico Pira Università degli Studi di Torino
Olio di oliva nella prevenzione della patologia cronicodegenerativa, con focus sul cancro Carlo La Vecchia Università degli Studi di Milano Enrico Pira Università degli Studi di Torino Olive oil and cancer:
More informationPREVALENCE, ASSOCIATED RISK FACTORS AND METHODS OF DIAGNOSING CERVICAL CANCER IN TWO HOSPITALS IN YAOUNDE, CAMEROON
Available online on www.ijarpb.com Research Article Received on 15/12/2012; Revised on 21/12/2012; Accepted on 23/12/2012 PREVALENCE, ASSOCIATED RISK FACTORS AND METHODS OF DIAGNOSING CERVICAL CANCER IN
More informationTISSUE TUMOR MARKER EXPRESSION IN
TISSUE TUMOR MARKER EXPRESSION IN NORMAL CERVICAL TISSUE AND IN CERVICAL INTRAEPITHELIAL NEOPLASIA, FOR WOMEN WHO ARE AT HIGH RISK OF HPV (HUMAN PAPILLOMA VIRUS INFECTION). Raghad Samir MD PhD Verksamhet
More informationA Case-Control Study of Risk Factors for Invasive Cervical Cancer among U.S. Women Exposed to Oncogenic Types of Human Papillomavirus
1574 Cancer Epidemiology, Biomarkers & Prevention A Case-Control Study of Risk Factors for Invasive Cervical Cancer among U.S. Women Exposed to Oncogenic Types of Human Papillomavirus Tammy S. Shields,
More informationPathology of the Cervix
Pathology of the Cervix Thomas C. Wright Pathology of the Cervix Topics to Consider Burden of cervical cancer 1 Invasive Cervical Cancer Cervical cancer in world Second cause of cancer death in women Leading
More informationUpdate of the role of Human Papillomavirus in Head and Neck Cancer
Update of the role of Human Papillomavirus in Head and Neck Cancer 2013 International & 12 th National Head and Neck Tumour Conference Shanghai, 11 13 Oct 2013 Prof. Paul KS Chan Department of Microbiology
More informationObjectives. Background. Background. Background. Background 9/26/16. Update on Cervical and HPV Screening Guidelines: To pap or not to pap?
Update on Cervical and HPV Screening Guidelines: To pap or not to pap? Marina Delazari Miller MD Clinical Assistant Professor Department of Obstetrics & Gynecology University of Iowa Hospitals and Clinics
More informationAbsolute Risk of a Subsequent Abnormal Pap among Oncogenic Human Papillomavirus DNA-Positive, Cytologically Negative Women
Absolute Risk of a Subsequent Abnormal Pap among Oncogenic Human Papillomavirus DNA-Positive, Cytologically Negative Women 2145 Philip E. Castle, Ph.D., M.P.H. 1 Sholom Wacholder, Ph.D. 1 Mark E. Sherman,
More informationREPRODUCTIVE ENDOCRINOLOGY
FERTILITY AND STERILITY VOL. 70, NO. 6, DECEMBER 1998 Copyright 1998 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. REPRODUCTIVE ENDOCRINOLOGY
More informationTARGETS To reduce the age-standardised mortality rate from cervical cancer in all New Zealand women to 3.5 per or less by the year 2005.
Cervical Cancer Key points Annually, around 85 women die from, and 230 women are registered with, cervical cancer. The decline in both incidence and mortality rates for cervical cancer has accelerated
More informationHPV AND CERVICAL CANCER
HPV AND CERVICAL CANCER DR SANDJONG TIECHOU ISAAC DELON Postgraduate Training in Reproductive Health Research Faculty of Medicine, University of Yaoundé 2007 INTRODUCTION CERVICAL CANCER IS THE SECOND
More informationContraception and cancerepidemiological
Contraception and cancerepidemiological evidence Hormonal contraception Combined Progestogen-only Philip C Hannaford University of Aberdeen Breast cancer and combined oral Re-analysis of individual data
More informationPrevalence and Determinants of High-risk Human Papillomavirus Infection in Women with High Socioeconomic Status in Seoul, Republic of Korea
RESEARCH COMMUNICATION Prevalence and Determinants of High-risk Human Papillomavirus Infection in Women with High Socioeconomic Status in Seoul, Republic of Korea Kidong Kim 1, Jin Ju Kim 2,3, Sun Mie
More informationReproductive Factors and Risk of Papillary Thyroid Cancer in Women
American Journal of Epidemiology Copyright O 2 by The Johns Hopkins University School of Hygiene and Public Health All rights reserved Vol. 5, Printed In USA. Reproductive Factors and Risk of Papillary
More informationPATTERN AND FACTORS AFFECTING PAP SMEAR TEST IN NABLUS, A RETROSPECTIVE STUDY
Middle East Journal of Family Medicine, 2004; Vol. 4 (4) PATTERN AND FACTORS AFFECTING PAP SMEAR TEST IN NABLUS, A RETROSPECTIVE STUDY Dr. Samar Ghazal/Musmar*, MD, American Board Certified *Clinical Assistant
More informationA Prospective Study of High-Grade Cervical Neoplasia Risk Among Human Papillomavirus-Infected Women
A Prospective Study of High-Grade Cervical Neoplasia Risk Among Human Papillomavirus-Infected Women Philip E. Castle, Sholom Wacholder, Attila T. Lorincz, David R. Scott, Mark E. Sherman, Andrew G. Glass,
More informationSupplementary Table 4. Study characteristics and association between OC use and endometrial cancer incidence
Supplementary Table 4. characteristics and association between OC use and endometrial cancer incidence a Details OR b 95% CI Covariates Region Case-control Parslov, 2000 (1) Danish women aged 25 49 yr
More information- ii - Rights c
- ii - Rights c - iii - Preface Preface to the third edition Since the first edition of the HPV Information Centre, GLOBOCAN, one of the landmark products of the International Agency for Research on Cancer
More informationNorthern Ireland cervical screening programme. Information for primary care and smear takers
Northern Ireland cervical screening programme Information for primary care and smear takers From January 2011, the Northern Ireland cervical screening programme will no longer invite women aged under 25
More informationOpinion: Cervical cancer a vaccine preventable disease
Opinion: Cervical cancer a vaccine preventable disease Leon Snyman Principal specialist at the Department of Obstetrics and Gynaecology, Gynaecological Oncology unit, University of Pretoria and Kalafong
More informationStrategies for data analysis: case-control studies
Strategies for data analysis: case-control studies Gilda Piaggio UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction World Health Organization
More information2
1 2 3 1. Usinger KM et al. Intrauterine contraception continuation in adolescents and young women: a systematic review. J Pediatr Adolesc Gynecol 2016; 29: 659 67. 2. Kost K et al. Estimates of contraceptive
More informationLactation and breast cancer risk
International Epidemiological Association 1999 Printed in Great Britain International Journal of Epidemiology 1999;28:396 402 Lactation and breast cancer risk H Furberg, a B Newman, a P Moorman b and R
More informationRisk factors for breast cancer in nulliparous women
British Journal of Cancer (1999) 79(11/12), 1923 1928 1999 Cancer Research Campaign Article no. bjoc.1998.0306 Risk factors for breast cancer in nulliparous women F Fioretti 1, A Tavani 1, C Bosetti 1,
More information14. Cancer of the Cervix Uteri
KEY FACTS 14. Cancer of the Cervix Uteri ICD-9 180 On average 78 cases of invasive cervical cancer were registered per year. Half of cases occurred under 49 years of age. 2% of female cancers. Higher than
More informationDRAFT COPY PERSONAL USE ONLY
Menopausal status, hormone replacement therapy use and risk of self-reported physician-diagnosed osteoarthritis in women attending menopause clinics in Italy Progetto Menopausa Italia Study Group 1, Fabio
More informationCervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013
Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines General Principles: Since its introduction in 1943, Papanicolaou (Pap) smear is widely
More informationGeneral practice. Abstract. Subjects and methods. Introduction. examining the effect of use of oral contraceptives on mortality in the long term.
Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46 000 women from Royal College of General Practitioners oral contraception study Valerie Beral, Carol Hermon, Clifford
More informationEffect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric casecontrol
Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric casecontrol study Victor Moreno, F Xavier Bosch, Nubia Muñoz, Chris J L M Meijer,
More informationSCCPS Scientific Committee Position Paper on HPV Vaccination
SCCPS Scientific Committee Position Paper on HPV Vaccination Adapted from Joint Statement (March 2011) of the: Obstetrical & Gynaecological Society of Singapore (OGSS) Society for Colposcopy and Cervical
More informationand treating joins with the top of canal). at risk for cervical carcinomas, cervix.
CERVICAL CANCER Worldwide, cervical cancer is twelfth most common and the fifth most deadly cancer in women. It affects about 16 per 100,000 women per year and kills about 9 per 100,000 per year. Cervical
More informationThe impact of the HPV vaccine in Scotland.
The impact of the HPV vaccine in Scotland Kevin.pollock@nhs.net Cervical cancer by deprivation Scotland 18 Cancer of the cervix uteri (ICD-10 C53) Age-standardised incidence and mortality rates by SIMD
More informationComparison of PAP test among high and non-high risk female Vaidya A 1
Original Article Comparison of PAP test among high and non-high risk female Vaidya A 1 1 Senior Consultant Gynaecologist and Obstetrician, Bhaktapur Hospital ABSTRACT A prospective study of pap smear in
More informationBRITISH COLUMBIA S CERVICAL CANCER SCREENING PROGRAM
BRITISH COLUMBIA S CERVICAL CANCER SCREENING PROGRAM DATE: NOVEMBER 19, 2016 PRESENTER: DR. DIRK VAN NIEKERK 1 Conflict of Interest Disclosure Nothing to disclose 2 ..in the beginning of the malady it
More informationRisk for anogenital cancer and other cancer among women hospitalized with gonorrhea
Acta Obstet Gynecol Scand 2001; 80: 757 761 Copyright C Acta Obstet Gynecol Scand 2001 Printed in Denmark All rights reserved Acta Obstetricia et Gynecologica Scandinavica ISSN 0001-6349 ORIGINAL ARTICLE
More informationRisk factors for the acquisition of genital warts: are condoms protective?
312 Sex Transm Inf 1999;75:312 316 Original article Academic Unit of Sexual Health Medicine, Sydney Hospital, Sydney, Australia LMWen C S Estcourt A Mindel Department of Public Health and Community Medicine,
More informationORAL CONTRACEPTIVES AND BREAST CANCER RISK IN TAIWAN, A COUNTRY OF LOW INCIDENCE OF BREAST CANCER AND LOW USE OF ORAL CONTRACEPTIVES
Int. J. Cancer: 77, 29 223 (998) 998 Wiley-Liss, Inc. ORAL CONTRACEPTIVES AND BREAST CANCER RISK IN TAIWAN, A COUNTRY OF LOW INCIDENCE OF BREAST CANCER AND LOW USE OF ORAL CONTRACEPTIVES Wei-Chu CHIE *,
More informationHuman Papillomavirus
Human Papillomavirus Dawn Palaszewski, MD Assistant Professor of Obstetrics and Gynecology University of February 18, 2018 9:40 am Dawn Palaszewski, MD Assistant Professor Department of Obstetrics and
More informationConcern about the potential increased risk of cardiovascular
Myocardial Infarction and Use of Low-Dose Oral Contraceptives A Pooled Analysis of 2 US Studies Stephen Sidney, MD, MPH; David S. Siscovick, MD, MPH; Diana B. Petitti, MD, MPH; Stephen M. Schwartz, PhD,
More informationCERVIX. MLS Basic histological diagnosis MLS HIST 422 Semester 8- batch 7 L12 : Dr. Ali Eltayb.
CERVIX MLS Basic histological diagnosis MLS HIST 422 Semester 8- batch 7 L12 : Dr. Ali Eltayb. CERVIX Most cervical lesions are: Most are Cervicitis. cancers ( common in women worldwide). CERVICITIS Extremely
More informationDepartment of Pathology, Kathmandu Medical College & Teaching Hospital, Sinamangal, Kathmandu, Nepal
Kathmandu University Medical Journal (2007), Vol. 5, No. 4, Issue 20, 461-467 Original Article Correlation of PAP smear findings with clinical findings and cervical biopsy Pradhan B 1, Pradhan SB 2, Mital
More informationMammographic density and risk of breast cancer by tumor characteristics: a casecontrol
Krishnan et al. BMC Cancer (2017) 17:859 DOI 10.1186/s12885-017-3871-7 RESEARCH ARTICLE Mammographic density and risk of breast cancer by tumor characteristics: a casecontrol study Open Access Kavitha
More informationGUIDELINE FOR SCREENING FOR CERVICAL CANCER: REVISED
GUIDELINE FOR SCREENING FOR CERVICAL CANCER: REVISED This guideline is a revised version of the guideline developed in February 2000, by the Cervical Cancer Screening Working Group. This revised version
More informationLong-Term Pill Use, High Parity Raise Cervical Cancer Risk Among Women with Human Papillomavirus Infection
D I G E S T S Long-Term Pill Use, High Parity Raise Cervical Cancer Risk Among Women with Human Papillomavirus Infection Use of oral contraceptives for five years or more appears to raise the risk of cervical
More informationCâncer Cervical e Nutrição 21 trabalhos
Câncer Cervical e Nutrição 21 trabalhos Cervical Cancer cancer showed that frequent consumption of dark green and yellow vegetables and fruit juices was associated with reduced risk of cervical cancer
More informationA meta-analysis of alcohol drinking and cancer risk
British Journal of Cancer (200) 85(), 700 705 doi: 0.054/ bjoc.200.240, available online at http://www.idealibrary.com on http://www.bjcancer.com A meta-analysis of alcohol drinking and cancer risk V Bagnardi,
More informationDownloaded from:
Ellingjord-Dale, M; Vos, L; Tretli, S; Hofvind, S; Dos-Santos-Silva, I; Ursin, G (2017) Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening
More informationCigarette tar yield and risk of upper digestive tract cancers: case control studies from Italy and Switzerland
Original article Annals of Oncology 14: 209 213, 2003 DOI: 10.1093/annonc/mdg074 Cigarette tar yield and risk of upper digestive tract cancers: case control studies from Italy and Switzerland S. Gallus
More informationSCREENING FOR CERVICAL CANCER BY PAP SMEAR
SCREENING FOR CERVICAL CANCER BY PAP SMEAR Pages with reference to book, From 229 To 231 Javaid H. Rizvi, Saadia Rasul, Basit Ghazali, Abid Jamal ( Department of Obstetrics and Gynaecology, The Aga Khan
More informationRisk factors in the development of cervical intraepithelial neoplasia in women with vulval warts
Genitourin Med 1988;64:316-20 Risk factors in the development of cervical intraepithelial neoplasia in women with vulval warts S A WALKINSHAW,* J DODGSON,* D J McCANCE,t I D DUNCAN* From the *Department
More informationCase-control study of thyroid cancer in Northern Italy: attributable risk
International Epidemiological Association 1999 Printed in Great Britain International Journal of Epidemiology 1999;28:626 630 Case-control study of thyroid cancer in Northern Italy: attributable risk Francesca
More informationSTUDY OF EARLY DETECTION OF CERVICAL CANCER BY PAP S SMEAR IN SELECTED SETTING OF PUDUCHERRY
STUDY OF EARLY DETECTION OF CERVICAL CANCER BY PAP S SMEAR IN SELECTED SETTING OF PUDUCHERRY *Thirumurugan. P, **Premila. E, ***Suresh Kanna. K *Associate Professor, Mother Theresa Post Graduate and Research
More informationDone by khozama jehad. Neoplasia of the cervix
Done by khozama jehad Neoplasia of the cervix An overview of cervical neoplasia very import. Most tumors of the cervix are of epithelial origin and are caused by oncogenic strains of human papillomavirus
More informationPREVENTION OF CERVICAL CANCER
PREVENTION OF CERVICAL CANCER Author: Dr R. Fuentes MBchb, Havana Spec. OB,GY-Havana- 2011 CONTENT TABLE Abbreviations 2 Introduction 4 The natural history of Cervical cancer 4 Risk Factors 4 Incidence
More informationRisk factors for precancerous lesions of the cervix in a population of Georgian women
Training Course in Sexual and Reproductive Health Research Geneva, 2 March 2009 Risk factors for precancerous lesions of the cervix in a population of Georgian women Maia Chiokadze, M.D. Medical Diagnostic
More informationWorking Group: This report will be written within the Second Malignancy Working Group.
Title: Human papillomavirus (HPV)-associated malignancies as second cancers in childhood cancer survivors: a report from the Childhood Cancer Survivor Study Working Group: This report will be written within
More informationEpidemiologic Study of Colposcopy in Clinical Centers of Kermanshah, Iran, during 2006 to 2011
Epidemiologic Study of Colposcopy in Clinical Centers of Kermanshah, Iran, during 2006 to 2011 Maryam Zangeneh (1) Maryam Hematti (2) Nasrin Jalilian (1) Seyedeh Nakisa Niknejad (3) (1) Department of Obstetrics
More informationA study of prevalence of Pap smear abnormalities in HIV seropositive women
Original Research Article A study of prevalence of Pap smear abnormalities in HIV seropositive women Yamini Shoba Vani 1*, Muddasani Priyadharshini 2 1 Assistant Professor, 2 Post Graduate Department of
More informationObjectives. HPV Classification. The Connection Between Human Papillomavirus and Oropharyngeal Cancer 6/19/2012
The Connection Between Human Papillomavirus and Oropharyngeal Cancer Jennifer L. Cleveland, DDS, MPH Dental Officer/Epidemiologist OSAP Annual Symposium June 23, 2012 Atlanta, GA National Center for Chronic
More informationClinically Microscopically Pathogenesis: autoimmune not lifetime
Vulvar Diseases: Can be divided to non-neoplastic and neoplastic diseases. The neoplastic diseases are much less common. Of those, squamous cell carcinoma is the most common. most common in postmenopausal
More informationStudy Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAltering Cervical Cancer s Trajectory. Mary S. Beattie, MD, MAS Medical Director, Women s Health BioOncology US Medical Affairs
Altering Cervical Cancer s Trajectory Mary S. Beattie, MD, MAS Medical Director, Women s Health BioOncology US Medical Affairs Objectives and Agenda Objectives: Appreciate cervical cancer (CC) burden Understand
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information9/18/2008. Cervical Cancer Prevention for Adolescent Populations Garcia. Faculty disclosure. Objectives. HPV Positivity by Age (UK)
Faculty disclosure Cervical Cancer Prevention for Francisco, MD, MPH Associate Professor Obstetrics & Gynecology Mexican American Studies Public Health Francisco, MD, MPH has no financial affiliations
More informationHPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options
HPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options R. Marshall Austin MD,PhD Magee-Womens Hospital of University of Pittsburgh Medical Center (UPMC) (raustin@magee.edu)
More informationtime since stopping smoking in Italy
Journal of Epidemiology and Community Health 1994;48:129-133 129 Acute myocardial infarction: association with time since stopping smoking in Italy Eva Negri, Carlo La Vecchia, Barbara D'Avanzo, Alessandro
More informationOral hygiene, dentition, sexual habits and risk of oral cancer
British Journal of Cancer (2000) 83(9), 238 242 doi: 0.054/ bjoc.2000.398, available online at http://www.idealibrary.com on Short Communication Oral hygiene, dentition, sexual habits and risk of oral
More informationstudy of the effect of birth year
British Journal of Cancer (1997) 75(1), 139-143 1997 Cancer Research Campaign Oral contraceptive use at a young age and the risk of breast cancer: an Icelandic, population-based cohort study of the effect
More informationNo HPV High Risk Screening with Genotyping. CPT Code: If Result is NOT DETECTED (x3) If Results is DETECTED (Genotype reported)
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 117 August 6, 2013 HPV High Risk Screening with Genotyping Contact: Dr. Jeffrey Wisotzkey, 717-851-1422 Director, Molecular Pathology
More informationStudy of Rate of Hysterectomy in Patients with Cervical Cancer Referring to Radiotherapy and Oncology Ward of Ahvaz Golestan Hospital in
International Journal of Advanced Biotechnology and Research (IJBR) ISSN 0976-2612, Online ISSN 2278 599X, Vol-7, Special Issue-Number5-July, 2016, pp945-950 http://www.bipublication.com Research Article
More informationNHSCSP proposals for cervical screening intervals. Comments and recommendations of Council of the British Society for Clinical Cytology
NHSCSP proposals for cervical screening intervals Comments and recommendations of Council of the British Society for Clinical Cytology The following paper is written on behalf of BSCC Council to express
More informationCERVICAL INTRAEPITHELIAL NEOPLASIA, CERVICAL CANCER, AND HPV
Anna Rev. Public Health 19%. 17:69-84 Copyrighr 0 I996 by Annual Reviews Inc. AN rights reserved CERVICAL INTRAEPITHELIAL NEOPLASIA, CERVICAL CANCER, AND HPV Elizabeth A. Holly Department of Epidemiology
More informationEffect of Oral Contraceptives on Risk of Cervical Cancer
Effect of Oral Contraceptives on Risk of Cervical Cancer Natthakan Vanakankovit MD*, Surasak Taneepanichskul MD* * Department of Obstetrics and Gynecology, Faculty of Medicine, King Chulalongkorn Memorial
More informationHuman papilloma viruses and cancer in the post-vaccine era
REVIEW 10.1111/j.1469-0691.2009.03032.x Human papilloma viruses and cancer in the post-vaccine era E. Galani and C. Christodoulou Metropolitan Hospital Medical Oncology, Athens, Greece Abstract Human papilloma
More informationIn 1981, we published results from a case-control. study involving 881 cases and 863 controls. not associated with any substantial overall risk,
Br. J. Cancer (1986) 54, 825-832 Menopausal oestrogens and breast cancer risk: An expanded case-control study L.A. Brinton, R. Hoover & J.F. Fraumeni, Jr Environmental Epidemiology Branch, National Cancer
More informationFolate intake and risk of oral and pharyngeal cancer
Original article Annals of Oncology 14: 1677 1681, 2003 DOI: 10.1093/annonc/mdg448 Folate intake and risk of oral and pharyngeal cancer C. Pelucchi 1 *, R. Talamini 2, E. Negri 1, F. Levi 3, E. Conti 4,
More informationFirst and subsequent asbestos exposures in relation to mesothelioma and lung cancer mortality
British Journal of Cancer (2007) 97, 1300 1304 All rights reserved 0007 0920/07 $30.00 www.bjcancer.com First and subsequent asbestos exposures in relation to mesothelioma and lung cancer mortality E Pira
More informationSmoking, human papillomavirus infection, and p53 mutation as risk factors in oropharyngeal cancer: a case-control study
RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES Smoking, human papillomavirus infection, and p53 as risk factors in oropharyngeal cancer: a case-control study PKS Chan *, JSY Chor, AC Vlantis, TL
More informationPAP smear. (Papanicolaou Test)
PAP smear (Papanicolaou Test) Is a screening test to prevent/ detect cancerous processes in endocervical canal It reduces the mortality caused by cervical cancer up to 80% M. Arbyn; et al. (2010). "European
More informationHuman Papillomaviruses and Cancer: Questions and Answers. Key Points. 1. What are human papillomaviruses, and how are they transmitted?
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Human Papillomaviruses
More informationTHERE IS CONSIDERABLE EVIdence
ORIGINAL CONTRIBUTION Relationship Between Long Durations and Different Regimens of Hormone Therapy and Risk of Breast Cancer Christopher I. Li, MD, PhD Kathleen E. Malone, PhD Peggy L. Porter, MD Noel
More informationEpidemiologic Profile of Type-Specific Human Papillomavirus Infection and Cervical Neoplasia in Guanacaste, Costa Rica
MAJOR ARTICLE Epidemiologic Profile of Type-Specific Human Papillomavirus Infection and Cervical Neoplasia in Guanacaste, Costa Rica Rolando Herrero, 1,a Philip E. Castle, 2,a Mark Schiffman, 2 M. Concepción
More informationScreening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA
Screening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA Cancer Care Ontario Cervical Cancer Screening Goals Increase patient participation in cervical screening Increase primary care
More informationHPV the silent killer, Prevention and diagnosis
HPV the silent killer, Prevention and diagnosis HPV Human Papilloma Virus is a name given for a silent virus transmitted sexually most of the time, a virus that spreads in the name of love, passion, and
More informationABSTRACT. Methods: A cross sectional study was carried out using questionnaires administered to female nurses and doctors
Knowledge, Attitudes and Practice regarding personal cervical cancer screening among Clinical Staff Working in Obstetrics and Gynaecology at Two Tertiary Institutions in Jamaica L Campbell 1 G Reynolds
More informationPostmenopausal hormone therapy and cancer risk
International Congress Series 1279 (2005) 133 140 www.ics-elsevier.com Postmenopausal hormone therapy and cancer risk P. Kenemans*, R.A. Verstraeten, R.H.M. Verheijen Department of Obstetrics and Gynaecology,
More informationCERVICAL CANCER FACTSHEET. What is cervical cancer?
CERVICAL CANCER FACTSHEET What is cervical cancer? ENGAGe is releasing a series of factsheets to raise awareness of gynaecological cancers and to support its network to work at a grassroots level. Take-up
More informationShould Anal Pap Smears Be a Standard of Care in HIV Management?
Should Anal Pap Smears Be a Standard of Care in HIV Management? Gordon Dickinson, M.D., FACP Professor of Medicine and Chief Infectious Diseases, Miller School of Medicine Short Answer: NO But 15-20 HPV
More information